Infosys Limited vs Liquidia Corporation Common Stock — how do they compare? Infosys Limited trades at $11.72 (market cap $46.25B), while Liquidia Corporation Common Stock trades at $33.47 (market cap $3.04B). The key difference: Infosys Limited is far larger — about 15.2× Liquidia Corporation Common Stock's market cap, and Infosys Limited pays a 4.56% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Liquidia Corporation Common Stock for 0 Days on average.
| INFY | LQDA | |
|---|---|---|
Market Cap | $46.25B | $3.04B |
Volume | 14,209,421 | 21,111,778 |
Sector | Technology | Health |
52-Week High | $20.22 | $91.03 |
52-Week Low | $10.49 | $22.02 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $44.00B | $2.94B |
Dividend Yield | 4.56% | — |
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal and strong profitability metrics including a 16.37% net margin and 32.12% ROE. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, signaling growth initiatives.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering modest upside. Risks include potential earnings volatility and competitive pressures in IT services. Analyst sentiment is mixed with 35% buy ratings, but strong cash flow and institutional interest support a stable investment case amid sector headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →